Neurology News

BOSTON — Treatment with Leqembi reduced markers of amyloid and tau in patients with early Alzheimer’s disease and slowed cognitive and functional decline at 18 months, according to data at the American Academy of Neurology annual meeting.

BOSTON — Long-term treatment with Vyvgart was safe, well-tolerated and effective in reducing immunoglobulin G antibody levels and improving clinical outcomes in patients with generalized myasthenia gravis.

In its first year, the Healio Honors peer-to-peer recognition program celebrated 65 health care professionals for their exemplary work in patient care, research, advocacy and mentorship. Year two of the program is now underway.

The nonprofit organization ElevateMeD Inc. has announced its 2023-’24 Scholars Program cohort, a group of 25 underrepresented medical students from across the country who each will be awarded a $16,500 tuition-based scholarship.

BOSTON — Two studies presented at the American Academy of Neurology meeting showed treatment with Aptiom improved quality of life scores and reduced frequency in patients with focal seizures.

The transition to standard time was associated with a transient increase in self-reported sleep disorders, while no problems with sleep were reported after the transition to daylight saving time, according to data in Neurology.

The addition of disulfiram and copper to chemotherapy did not result in a significant survival benefit for patients with recurrent glioblastoma, according to data published in JAMA Network Open.

Donanemab slowed cognitive and functional decline in early Alzheimer’s disease, according to the results of a phase 3 study.

BOSTON — Transcranial direct current stimulation of the dorsolateral prefrontal cortex increased activation of the area and improved self-reported fatigue in patients with MS, Giuseppina Pilloni, PhD, says in this Healio video.

BOSTON — Treatment with an investigational combination of low-dose pramipexole and rasagiline led to less excessive daytime sleepiness and fewer adverse events compared with pramipexole alone in early Parkinson’s disease, research showed.